Porcilis Pesti

Country: Unjoni Ewropea

Lingwa: Ingliż

Sors: EMA (European Medicines Agency)

Ixtrih issa

Ingredjent attiv:

Classical Swine Fever Virus (CSFV) -E2 subunit antigen

Disponibbli minn:

Intervet International BV

Kodiċi ATC:

QI09AD04

INN (Isem Internazzjonali):

Adjuvanted vaccine against classical swine fever

Grupp terapewtiku:

Pigs

Żona terapewtika:

Immunologicals for suidae

Indikazzjonijiet terapewtiċi:

Active immunisation of pigs from the age of 5 weeks onwards to prevent mortality and to reduce clinical signs of Classical Swine Fever, as well as to reduce infection with and excretion of CSF field virus.The onset of protection is 2 weeks.The duration of protection is 6 months.

Sommarju tal-prodott:

Revision: 12

L-istatus ta 'awtorizzazzjoni:

Withdrawn

Data ta 'l-awtorizzazzjoni:

2000-06-09

Fuljett ta 'informazzjoni

                                B. PACKAGE LEAFLET
14/17
PACKAGE LEAFLET
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE
MANUFACTURING
AUTHORISATION
HOLDER
RESPONSIBLE
FOR
BATCH
RELEASE, IF DIFFERENT
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Porcilis Pesti emulsion for injection for pigs
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Each dose of 2 ml contains:
120 Elisa Units Classical Swine Fever Virus-E2 subunit antigen
Liquid paraffin as adjuvant: 941.4 mg
4.
INDICATION(S)
_ _
Active immunisation of pigs from the age of 5 weeks onwards to prevent
mortality and to reduce clinical
signs of Classical Swine Fever, as well as to reduce infection with
and excretion of CSF field virus.
The onset of protection is 2 weeks.
The duration of protection is 6 months.
5.
CONTRAINDICATIONS
None
6.
ADVERSE REACTIONS
A local and in most cases transient swelling at the injection site may
occur up to 4 weeks after administration
of each dose of the vaccine. Transient hyperthermia may occur post the
second dose.
Abscesses may be observed at the injection site.
Since safety after giving both inoculations at the same site
has not been examined, it is advised to carry out the second
vaccination at a different site than the first
vaccination.
If you notice any serious side effects or other effects not mentioned
in this leaflet, please inform your
veterinary surgeon.
7.
TARGET SPECIES
Pigs
15/17
8.
DOSAGE FOR EACH SPECIES, ROUTES AND METHOD OF ADMINISTRATION
Administer one dose (2 ml) by deep intramuscular injection in the neck
area behind the ear.
Vaccination scheme:
Basic vaccination: Inject one dose per pig followed by a second
injection 4 weeks after the first injection.
Re-vaccination: Every 6 months, using a single dose.
9.
ADVICE ON CORRECT ADMINISTRATION
Shake well before use.
Before use, allow the vaccine to reach room temperature.
Use sterile syringes and needles.
It is recommended to use a closed multiject vaccination system.
10.
WIT
                                
                                Aqra d-dokument sħiħ
                                
                            

Karatteristiċi tal-prodott

                                ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
1/17
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Porcilis Pesti emulsion for injection for pigs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 2 ml contains:
ACTIVE SUBSTANCE:
Classical Swine Fever Virus (CSFV) -E2 subunit antigen: 120 Elisa
Units (EU)
ADJUVANT:
941.4 mg liquid paraffin
EXCIPIENTS:
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Emulsion for injection.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Pigs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of pigs from the age of 5 weeks onwards to prevent
mortality and to reduce clinical
signs of Classical Swine Fever, as well as to reduce infection with
and excretion of CSF field virus.
The onset of protection is 2 weeks.
The duration of protection is 6 months.
_ _
4.3
CONTRAINDICATIONS
None
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Vaccinate only healthy animals.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY
MEDICINAL PRODUCT TO
ANIMALS
To the user:
2/17
This product contains mineral oil. Accidental injection/self injection
may result in severe pain and
swelling, particularly if injected into a joint or finger, and in rare
cases could result in the loss of the
affected finger if prompt medical attention is not given.
If you are accidentally injected with this product, seek prompt
medical advice even if only a very small
amount is injected and take the package leaflet with you.
If pain persists for more than 12 hours after medical examination,
seek medical advice again.
To the physician:
This product contains mineral oil. Even if small amounts have been
injected, accidental injection with this
product can cause intense swelling, which may, for example, result in
ischaemic necrosis and even the loss
of a digit. Expert, PROMPT, surgical attention is required and may
necessitate early incision and irrigation
of the injected area, especially where the
                                
                                Aqra d-dokument sħiħ
                                
                            

Dokumenti f'lingwi oħra

Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Bulgaru 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Bulgaru 06-10-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Spanjol 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Spanjol 06-10-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ċek 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ċek 06-10-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Daniż 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Daniż 06-10-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ġermaniż 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ġermaniż 06-10-2011
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ġermaniż 26-02-2009
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Estonjan 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Estonjan 06-10-2011
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Estonjan 26-02-2009
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Grieg 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Grieg 06-10-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Franċiż 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Franċiż 06-10-2011
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Franċiż 26-02-2009
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Taljan 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Taljan 06-10-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Latvjan 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Latvjan 06-10-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Litwanjan 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Litwanjan 06-10-2011
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Litwanjan 26-02-2009
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ungeriż 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ungeriż 06-10-2011
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ungeriż 26-02-2009
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Malti 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Malti 06-10-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Olandiż 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Olandiż 06-10-2011
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Olandiż 26-02-2009
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Pollakk 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Pollakk 06-10-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Portugiż 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Portugiż 06-10-2011
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Portugiż 26-02-2009
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Rumen 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Rumen 06-10-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Slovakk 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Slovakk 06-10-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Sloven 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Sloven 06-10-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Finlandiż 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Finlandiż 06-10-2011
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Finlandiż 26-02-2009
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Svediż 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Svediż 06-10-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Norveġiż 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Norveġiż 06-10-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Iżlandiż 06-10-2011
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Iżlandiż 06-10-2011

Ara l-istorja tad-dokumenti